I am a breastfeeding mother and i want to know if it is safe to use BRN 1885770? Is BRN 1885770 safe for nursing mother and child? Does BRN 1885770 extracts into breast milk? Does BRN 1885770 has any long term or short term side effects on infants? Can BRN 1885770 influence milk supply or can BRN 1885770 decrease milk supply in lactating mothers?
- DrLact safety Score for BRN 1885770 is 5 out of 8 which is considered Unsafe as per our analyses.
- A safety Score of 5 indicates that usage of BRN 1885770 may cause serious side effects in breastfed baby.
- Our study of different scientific research indicates that BRN 1885770 may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using BRN 1885770 .
- It is recommended to evaluate the advantage of not breastfeeding while using BRN 1885770 Vs not using BRN 1885770 And continue breastfeeding.
- While using BRN 1885770 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Retinoid which is a synthetic derivative of vitamin A. It is a cis-configuration of Tretinoin, an acid form of vitamin A.Indicated in the treatment of severe forms of acne. At latest update no published data on excretion into breast milk were found. Despite of a high plasma protein-binding capacity, it is a highly lipophilic substance, hence, it is presumed to accumulate in breastmilk. The natural form of vitamin A is readily excreted into breastmilk. In addition to being a potent teratogen (Shirazi 2015), which affects pregnancy, it has been shown to decrease all pituitary hormones levels (Karadag 2011 and 2015) along with other potential serious side effects associated to the use of BRN 1885770. It may cause galactorrhea (Larsen 1985). A safer alternative should be preferred until more published data on this drug related to breastfeeding is available, especially during the neonatal period and in case of prematurity.
No information is available on the use of BRN 1885770 during breastfeeding. Various topical agents that are less likely to be absorbed by the mother may be preferred during breastfeeding, especially while nursing a newborn or preterm infant.
A woman who had weaned her infant 18 months previously developed a nipple discharge from her right breast after 5.5 months of therapy with BRN 1885770. Microbiological, hormonal (including prolactin), radiologic, and physical examinations were otherwise normal. One month after discontinuing BRN 1885770, the discharge ceased. After BRN 1885770 was reinstituted at the same dose, the discharge reappeared within 10 days.[1] The galactorrhea was probably caused by BRN 1885770. A review of adverse reaction reports on retinoids causing a breast reaction submitted to a French pharmacovigilance center found 22 cases of gynecomastia was associated with BRN 1885770 use. Fourteen of the cases were gynecomastia, 6 were galactorrhea and 2 were of both gynecomastia and galactorrhea. Gynecomastia and/or galactorrhea was unilateral for almost half of the reported retinoid cases. The median time of onset was 90 days (IQR 39 to 347 days). The outcome was known for 27 of 31 patients and a total recovery after withdrawal of retinoid was observed for 63% of them.[2]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.